Business
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced participation in the AASLD Liver Meeting 2025. The company will deliver two presentations, including one oral and one poster presentation, highlighting data from the NAVIGATE trial assessing belapectin for the treatment of MASH cirrhosis. The meeting will be held November
About this update from Galectin Therapeutics Inc.
[{"type":"image","alt":"Galectin Therapeutics Inc.","displaySize":"","headline":null,"caption":"Galectin Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":267,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/a11c82d809909171dee0b6a5e015c96b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fDKup_DxRvH1q911Cik6yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a11c82d809909171dee0b6a5e015c96b","width":267,"height":65}},"lazy":false},{"type":"text","content":"NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced participation in the AASLD Liver Meeting 2025. The company will deliver two presentations, including one oral and one poster presentation, highlighting data from the NAVIGATE trial assessing belapectin for the treatment of MASH cirrhosis. The meeting will be held November 7-11, 2025, in Washington, DC, USA.","length":540,"tagName":"p"},{"type":"text","content":"“We are thrilled that the NAVIGATE trial data has been selected for oral presentation at AASLD, reflecting both the strength of our findings and the growing scientific interest in addressing MASH cirrhosis. These results highlight the urgent unmet need for therapies that can slow disease progression and prevent serious complications such as varices. The recognition by the hepatology community underscores the potential of belapectin to change the treatment landscape for this vulnerable patient population. We look forward to continuing to drive progress in this important condition,” said Joel Lewis, Chief Executive Officer at Galectin Therapeutics.","length":654,"tagName":"p"},{"type":"text","content":"Presentation DetailsOral Presentation ","length":38,"tagName":"p"},{"type":"text","content":"Title: Belapectin Reduces Liver Stiffness Progression and Prevents Varices at 18 Months in MASH Cirrhosis: Results from the NAVIGATE TrialAbstract Number: 0145Session: Management of Portal Hypertension: From Considerations in MASLD and the Assessment of FrailtyPresenter: Raj VuppalanchiDate, time & location: Nov 10, 2025: 2:00 PM - 3:30 PM EST","length":358,"tagName":"p"},{"type":"text","content":"Poster Presentation...